Pubblicazioni

JQ-1/bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of prosurvival mechanisms

2023 - EXPERIMENTAL HEMATOLOGY

Arena, Andrea; Romeo, Maria Anele; Benedetti, Rossella; Gilardini Montani, Maria Saveria; Cirone, Mara

The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment

2022 - BIOMOLECULES

Santoni, G.; Amantini, C.; Maggi, F.; Marinelli, O.; Santoni, M.; Morelli, M. B.

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

2018 - NEW ENGLAND JOURNAL OF MEDICINE

Mateos, M. -V.; Dimopoulos, M. A.; Cavo, M.; Suzuki, K.; Jakubowiak, A.; Knop, S.; Doyen, C.; Lucio, P.; Nagy, Z.; Kaplan, P.; Pour, L.; Cook, M.; Grosicki, S.; Crepaldi, A.; Liberati, A. M.; Campbell, P.; Shelekhova, T.; Yoon, S. -S.; Iosava, G.; Fujisaki, T.; Garg, M.; Chiu, C.; Wang, J.; Carson, R.; Crist, W.; Deraedt, W.; Nguyen, H.; Qi, M.; San-Miguel, J.; Foa, R.

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma

2017 - CLINICAL RADIOLOGY

Lacognata, C.; Crimi, F.; Guolo, A.; Varin, C.; De March, E.; Vio, S.; Ponzoni, A.; Barila, G.; Lico, A.; Branca, A.; De Biasi, E.; Gherlinzoni, F.; Scapin, V.; Bissoli, E.; Berno, T.; Zambello, R.